ScreenerHero

OBIO Orchestra BioMed Holdings, Inc.

NAS · US · Healthcare · Biotechnology · orchestrabiomed.com
5.660USD-3.08%Mkt Cap: 340.19M $P/E: —

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap340.19M USD
Enterprise Value321.91M USD
Revenue (TTM)31.98M USD
Gross Profit33.29M USD
Net Income (TTM)-52.70M USD
Revenue/Share0.54 USD
Last Price5.660 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees86
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.87
PEG—
EV/EBITDA-5.58
EV/Revenue10.07
P/S10.98
P/B18.19
EPS (TTM)-0.83
EPS (Forward)-1.51
52W Range
2.20080% of range6.500
52W High6.500 USD
52W Low2.200 USD
Profitability
Gross Margin99.43%
Oper. Margin-25404.55%
EBITDA Margin-180.27%
Profit Margin-157.40%
ROE-98.38%
ROA-45.88%
Growth
Revenue Growth-89.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-48.96M USD
CapEx (TTM)489.00K USD
FCF Margin-99.49%
FCF Yield-9.35%
Net Debt-39.20M USD
Net Debt/EBITDA0.68
Balance Sheet
Debt/Equity0.30
Current Ratio8.26
Quick Ratio8.17
Book Value/Sh0.32 USD
Cash/Share1.83 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.43 USD
Upside (mean)+119.6%
Target Range9.000 USD – 20.00 USD
9.000+119.6% to mean20.00
# Analysts7
Ownership
Shares Out.60.11M
Float32.96M
Insiders24.42%
Institutions47.80%
Short Interest
Short Ratio6.0d
Short % Float6.41%
Short % Out.3.95%
Shares Short2.37M
Short (prev mo.)2.38M
Technical
SMA 505.196 (+8.9%)
SMA 2004.406 (+28.5%)
Beta0.52
S&P 52W Chg16.45%
Avg Vol (30d)336.27K
Avg Vol (10d)287.80K
Technical Indicators
RSI (14)50.6
MACD0.2557
MACD Signal0.3413
MACD Hist.-0.0856
BB Upper6.503 USD
BB Middle5.899 USD
BB Lower5.295 USD
BB Width20.46%
ATR (14)0.3385 USD
Vol Ratio (20d)0.64x